Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906390 | 0.94 | MAP2K1 (0.48) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24088780 | 0.90 | MAP2K1 (0.46) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30035017 | 0.89 | MAP2K1 (0.57) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20565269 | 0.89 | MAP2K1 (0.57) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26047319 | 0.88 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL24349753 | 0.87 | MAP2K1 (0.47) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL22045822 | 0.86 | MAP2K1 (0.58) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24350870 | 0.84 | MAP2K1 (0.44) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24906176 | 0.84 | MAP2K1 (0.40) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL24349946 | 0.82 | DHODH (0.43) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | ADH1C, SIK1, PKN2 | MAP2K1 550/4885MAP2K2 425/4885CYP3A4 884/4885 |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885CYP3A4 726/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885CYP3A4 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.